

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During consultation, consultees commented that there may be people that cannot use the device due to inadequate coordination skills (such as young children) or the inability to generate sufficient negative pressure to deliver the drug effectively (such as people with reduced lung function)
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The Committee may need to take into account any preferences for one technology over another because of the difficulties in using the devices in its considerations of the evidence and subsequent recommendations.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

The 'other considerations section of the scope has been amended to highlight the fact that there may be people who have difficulties using the inhaler device.
--

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Helen Chung.....

Date: 28/01/2011